

FORM PTO-1390
(REV. 01-2003)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

CL001362-US

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

TB10/506513

INTERNATIONAL APPLICATION NO.
PCT/US03/06667

INTERNATIONAL FILING DATE
05 March 2003

PRIORITY DATE CLAIMED
05 March 2002

TITLE OF INVENTION

Isolated Human Transporter Proteins, Nucleic Acid Molecules Encoding Human Transporter Proteins, and Uses Thereof

APPLICANT(S) FOR DO/EO/US

Qi, Rong, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ has been communicated by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A preliminary amendment.
14. ☐ An Application Data Sheet under 37 CFR 1.76.
15. ☐ A substitute specification.
16. ☐ A power of attorney and/or change of address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information:

10/506513

DT09 Rec'd PCT/PTO 03 SEP 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: QI, Rong, et al.

Art Unit:

Serial No. (to be assigned)

Examiner:

Filed: September 3, 2004

Atty. Docket: CL001362-US

For: ISOLATED HUMAN TRANSPORTER PROTEINS,
NUCLEIC ACID MOLECULES ENCODING HUMAN
TRANSPORTER PROTEINS, AND USES THEREOF

**Submission Of Sequence Listing
Under 37 CFR § 1.821(a)**

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. § 1.821(a), applicants submit the Sequence Listing, including the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

It is respectfully believed that this application complies with the Sequence Listing requirements and is now in condition for processing.

Respectfully submitted,

Date: September 3, 2004

By: 

Lin Sun-Hoffman, Ph.D., Reg No. 47,983

Celera Genomics
45 West Gude Drive, C1-316
Rockville, MD 20850
Tel: 240-453-3067
Fax: 240-453-3084